Minutes of the special meeting of the WADA Executive Committee
15 November 2013, Johannesburg, South Africa

The meeting began at 9.00 a.m.

1. Welcome, roll call and observers

THE CHAIRMAN called to order the meeting of the Executive Committee of the World Anti-Doping Agency, noting that there were a number of Foundation Board members present and that they were welcome as observers.

The purpose of the morning’s meeting, as he knew the members were well aware, was to look at the work that had been done for a long period of time, culminating in the proposal for the revisions to the Code. First, however, he would take the members through each of the international standards, as it was the task of the Executive Committee to approve each of the standards.

He distributed the roll call and asked the members and observers to sign it.

The following members attended the meeting: Mr John Fahey, AC, President and Chairman of WADA; Professor Arne Ljungqvist, WADA Vice-Chairman, IOC Member and Chairman of the WADA Health, Medical and Research Committee; Ms Beckie Scott, Member of the IOC and Member of the IOC Athletes’ Commission; Sir Craig Reedie, IOC Vice President; Mr Fikile Mbalula, Minister of Sport and Recreation, South Africa; Mr Gian Franco Kasper, IOC Member and President of the FIS; Dr Richard Budgett, representing Mr Francesco Ricci Bitti, President of the International Tennis Federation and President of ASOIF; Professor Ugur Erdener, IOC Member, President of World Archery; Mr Michael Gottlieb, representing the US Government; Mr Yoshitaka Sakurada, Minister in Charge of Sports, Japan; Mr Andrew Godkin, representing Mr Peter Dutton, Minister for Sport, Australia; Ms Valérie Fourneyron, Minister of Sports, Youth, Non-Formal Education and Voluntary Organisations, France; Mr Ernesto Irurueta, representing Mr Francisco Boza, Minister of Sport, Peru and President, Americas Sports Council (CADE), Peru; Mr David Howman, WADA Director General; Mr Rune Andersen, Standards and Harmonisation Director, WADA; Mr Frédéric Donzé, Director of the European Regional Office and IF Relations, WADA; Mr Rob Koehler, Education and Program Development Director, WADA; Ms Julie Massé, Communications Director, WADA; Dr Olivier Rabin, Science Director, WADA; Dr Alan Vernec, Medical Director, WADA and Mr Olivier Niggli, Legal Director, WADA.

The following observer signed the roll call: Shaw Kgathi.

− 1.1 Disclosures of conflicts of interest

THE CHAIRMAN asked if there were any conflicts of interest that the members wished to disclose. He noted that this was not the case.

2. 2015 World Anti-Doping Code

THE CHAIRMAN said that the final matter he wanted the members to address was the Code itself. The Executive Committee had the Code including the amendments dealt with and approved by the Executive Committee at its meeting on Tuesday. It was the members’ prerogative to make a recommendation to the Foundation Board, which would shortly convene, that the Code, with those amendments, be approved by the Foundation Board. Was that the members’ wish? He saw no objection, so he thanked the members for their support.

DECISION
Executive Committee to recommend to the Foundation Board that the 2015 World Anti-Doping Code be approved.
3. International standards

- 3.1 2015 International Standard for Laboratories (ISL)

  THE CHAIRMAN noted that the ISL session had been chaired by Professor Ljungqvist.

  PROFESSOR LJUNGQVIST informed the members that the session had been very good, and there had been several interventions and quite interesting discussions. One issue had come out of the session and it had to do with further testing and long-term storage, and he believed the Mr Young had the amended text to explain to the members.

  MR YOUNG said that this was an issue on which the team had been working for a while, and it had to do with the unique circumstance of samples that were collected at major events such as the Olympic Games and then stored for future analysis. There was a unique situation whereby there were 1,000 or 2,000 samples, the A samples had been opened and the B samples had not, and then they were shipped to another laboratory for long-term storage and analysis at a further time. One first had to deal with the situation of all the opened A bottles, and the change to the international standard said that one could either reseal those bottles individually or put them into boxes or containers that were separately sealed. When they were received by the receiving laboratory, rather than go through and examine each bottle at that time, they could be stored and examined when it was time to analyse those samples four, five, six, seven, eight, nine, or ten years later. At that point, sometimes there was an A sample that had been resealed and then there was the original sealed B. Frequently, there was not enough sample left in the A and sometimes there was no sample left in the A after the testing at the games. What would one do then? The testing authority could go forward with an analysis of the A sample as was currently done in normal circumstances, either for the initial screen or for the A confirmation or, frequently, there would be issues with chain of custody or something like that with the A, and it could go forward and have the B sample split under the observation of an independent witness, and then treat the first bottle from the B split as an A sample and the second bottle as a B sample; so, when the B bottle was split, the independent witness would seal the second bottle, the analysis would proceed on the first bottle and, if there was an adverse analytical finding from the first bottle, the athlete would be invited in to watch the unsealing of the second bottle and watch the analysis of that B sample. In connection with that, there was a clarification in the definition of further analysis. Those were the proposed changes.

  THE CHAIRMAN asked if there were any comments. There was a paper before the members that fully explained the amendment. As there were no questions or comments, he understood that the Executive Committee was happy to approve the amendments as outlined. He asked the Executive Committee to approve the ISL with the amendment just approved.

  DECISION

  ISL as amended approved.

- 3.2 2015 International Standard for the Protection of Privacy and Personal Information (ISPPPI)

  THE CHAIRMAN asked the chair of the ISPPPI session to indicate to the Executive Committee whether she was aware of any changes. Were there any matters she wished to report back to the Executive Committee from the interventions made the previous day on the standard?

  MS FOURNEYRON said that the ISPPPI session had been a good session and no modifications had been put forward.

  THE CHAIRMAN thanked Ms Fourneyron. As there were no matters for change, he asked the Executive Committee for its approval of the ISPPPI in the form the members were all fully aware of.

  DECISION

  ISPPPI approved.

- 3.3 2015 International Standard for Testing and Investigations (ISTI)

  THE CHAIRMAN said that the chair of the ISTI session the previous day had been Mr Godkin.

  MR GODKIN observed that there had been overwhelming support for the standard.

  THE CHAIRMAN asked for the members’ approval of the standard.
3.4 2015 International Standard for Therapeutic Use Exemptions (ISTUE)

THE CHAIRMAN asked Professor Erdener, who had chaired the ISTUE session the previous day, if there were any matters he wished to report on.

PROFESSOR ERDENER said that there had been a very good session and no major changes had been put forward.

THE CHAIRMAN sought the members’ approval of the ISTUE.

DECISION

ISTUE approved.

The meeting adjourned at 9.15 a.m.

FOR APPROVAL

JOHN FAHEY, AC
PRESIDENT AND CHAIRMAN OF WADA